Document is current
Any future updates will be listed below
-
Authors
Bibi, Igor
Schaffert, Daniel
Blanke, Philipp
Illian, Lorenz
Lenzing, Federico
Martin, Niklas
Leipe, Jan
März, Winfried
Stach, Ksenija
Olsavszky, Victor
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 29 December 2024
Accepted: 13 October 2025
First Online: 20 October 2025
Declarations
:
: Jan Leipe: research support/clinical trials: Abbott, Boehringer, Pfizer, Gilead, Novartis; Scientific advisory board/speakers of bureau: Abbvie, Biogen, BMS, Galapagos, Lilly, medac, MSD, Novartis, Roche, Sanofi, UCB. All outside the submitted work; Winfried März: grants and personal fees from AMGEN, grants and personal fees from Sanofi, grants and personal fees from Amryt Pharmaceuticals, grants and personal fees from Abbott Diagnostics, grants and personal fees from Akzea Therapeutics, grants from Novartis Pharma GmbH, other from SYNLAB Holding Deutschland GmbH, personal fees from SOBI. All outside the submitted work; Ksenija Stach: Research support/studies: Amgen, AstraZeneca, Daiichi Sankyo, Lilly, Novartis. Lecturing activities: AbbVie, Amgen, AstraZeneca, Berlin Chemie, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Ultragenyx. Consultancy: Amgen, MSD. All outside the submitted work; All other authors have no conflicts of interest.
: This manuscript involves research with human participants, with informed consent obtained for both study participation and publication of information. No identifying information is included, and all identifying details have been removed to ensure anonymity.
